Simon Rasmussen

2 months ago | nature.com | Lili Niu |Sara Stinson |Jens-Christian Holm |Simon Rasmussen |Torben Frøstrup Hansen

AbstractOur current understanding of the determinants of plasma proteome variation during pediatric development remains incomplete. Here, we show that genetic variants, age, sex and body mass index significantly influence this variation. Using a streamlined and highly quantitative mass spectrometry-based proteomics workflow, we analyzed plasma from 2,147 children and adolescents, identifying 1,216 proteins after quality control.

May 8, 2024 | biorxiv.org | Jakob Nybo Nissen |Pau Piera Lindez |Simon Rasmussen

AbstractNew methods for metagenomic binning are typically evaluated using benchmarking software, and become tuned to maximize whatever criterion is measured by the benchmark. Subtleties in benchmarking procedures can cause misleading evaluations, derailing method development. Differences between procedures used to evaluate binning tools make them hard to compare, which slows progress in the field.

May 1, 2024 | medrxiv.org | Jonas Meisner |Michael Eriksen Benros |Simon Rasmussen

The authors have declared no competing interest. Lundbeck Foundation (R380-2021-1225 and R278-2018-1411) and the Novo Nordisk Foundation (NNF14CC0001 and NNF23SA0084103). I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Apr 1, 2024 | jrheum.org | Lykke M. Ørnbjerg |Kathrine Rugbjerg |Stylianos Georgiadis |Simon Rasmussen

RESULTSPatients. We included data on 12,262 biologic-naïve patients with PsA starting treatment with a first TNFi in a real-world setting between January 1, 2009, and December 31, 2018. Among these patients, 4329 patients later initiated a second TNFi and 1240 patients a third TNFi. Considering the first TNFi treatment course, etanercept was the most frequently prescribed drug (35% of patients), followed by adalimumab (30%), infliximab (17%), golimumab (13%), and certolizumab pegol (7%).

Mar 27, 2024 | mondaq.com | Rasmus Mandøe Jensen |Simon Rasmussen |Jónas Már Torfason

Recently, the ubiquitous activity of staking in crypto-markets has been supplemented with so-called "liquid staking". But liquid staking carries its own regulatory risks which can be different and more significant than those applicable to the token being staked. Below, investment services and crypto-asset specialists from Plesner consider these important risks.